AHL
HAE icon

Abel Hall LLC’s Haemonetics HAE Stock Holding History

Abel Hall LLC’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$224K Buy
+2,984
New +$192K 0.04% 661
2026
Q1 		– Sell
-3,130
Closed -$251K – 882
2025
Q4 		$251K Buy
+3,130
New +$210K 0.06% 431

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Abel Hall LLC's HAE Position: Q2 2026 in Review

Abel Hall LLC opened a new position in Haemonetics (HAE) in Q2 2026: 2,984 shares worth $224K. The stake represents 0.04% of the portfolio and ranks #661 among its holdings. This is a return to the name: Abel Hall LLC previously reported a position in HAE as recently as Q4 2025.

Abel Hall LLC first reported a position in HAE in Q4 2025 and has held it in 2 quarters since. The position peaked at $251K in Q4 2025. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Abel Hall LLC held 2,984 shares of Haemonetics worth $224K as of Q2 2026.
  • Haemonetics was a new Abel Hall LLC position in Q2 2026.
  • Haemonetics made up 0.04% of Abel Hall LLC's portfolio in Q2 2026, its #661 holding.
  • Abel Hall LLC first reported a position in Haemonetics in Q4 2025 and has held it in 2 quarters since.
  • Abel Hall LLC's Haemonetics position peaked at $251K in Q4 2025.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.